Emergent BioSolutions: Top Official Warned That Vaccine Plant Had to Be ‘Monitored Closely`
Mr. de Notaristefani, a former top executive at two major pharmaceutical companies, cited “significant” personnel problems, writing that plans to increase staffing seemed “inadequate to enable the company to manufacture at the required rate.” He also noted that audits by the F.D.A. and individual companies that had hired Emergent “highlighted the need for extensive training…